Nasdaq:LIVN
LivaNova PLC
LIVN is a leading global medical device innovator specializing in advanced heart pump technologies and valve replacement systems to treat severe cardiovascular conditions.
Key Metrics
Investment Thesis
Bull Case
LIVN offers compelling value through its monopoly-like position in the LVAD market, which generates predictable cash flows essential for funding R&D and acquisitions. The company's strong balance sheet with $635.6M in cash allows it to weather regulatory hurdles and invest in next-generation minimally invasive technologies without immediate dilution. Long-term demographic trends favoring heart failure treatments ensure sustained demand growth for its established product portfolio over the coming decade.
Bear Case
Investors should be concerned by the severe net loss of $242.5M which suggests underlying profitability issues not fully explained by one-time items alone. The company carries a substantial long-term debt load of $345.2M with limited recent debt issuances, increasing financial leverage and interest sensitivity in a potential rate hike environment. Recent declines in non-operating income and high operating expenses relative to revenue growth indicate margin compression that could persist if pricing power weakens.
About LivaNova PLC
LIVN develops, manufactures, and markets advanced cardiovascular medical devices globally, with a primary focus on left ventricular assist systems (LVADs) and heart valve replacement solutions. The company serves hospitals and outpatient centers worldwide through its network of sales and service representatives. Key products include the HeartMate series of pumps for end-stage heart failure patients and the Perceval mechanical aortic valve.
Analysis
Management Discussion
Despite a strong operating profit of $199.4M, the company reported a net loss of $242.5M in the latest period, primarily due to significant non-operating losses and one-time charges that pushed profit from continuing operations into negative territory. Revenue growth remained steady at $1.39B, reflecting consistent demand for heart failure therapies, though the sharp decline in net income highlights volatility in earnings quality relative to top-line performance. Cash flow from operations of $254.3M provided a cushion against capital expenditures of $81.0M and substantial debt repayments totaling $280.9M.
Industry Overview
The global cardiovascular medical device market is experiencing robust growth driven by an aging population and rising prevalence of heart failure, creating lucrative opportunities for specialized innovators like LIVN. Regulatory bodies worldwide are increasingly demanding rigorous clinical trial data and real-world performance metrics, raising the cost of entry but also protecting established players with proven track records. Mergers and acquisitions activity in this sector is intensifying as companies seek to expand their product portfolios beyond durable implants into consumables and software-enabled diagnostics.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.02B | $1.15B | $1.25B | $1.39B |
| Cost of Revenue | $314.6M | $382.3M | $382.6M | $448.2M |
| Gross Profit | $707.2M | $771.2M | $870.9M | $939.9M |
| Operating Expenses | $784.0M | $839.7M | $741.8M | $740.5M |
| Operating Income | $-76.8M | $-68.5M | $129.1M | $199.4M |
| R&D | $155.8M | $193.8M | $182.5M | $185.8M |
| G&A | $469.2M | $518.1M | $526.3M | $548.8M |
| Stock-Based Comp | $44.8M | $36.4M | $33.9M | $36.3M |
| Depreciation | $22.4M | $24.7M | $25.1M | $28.6M |
| Amortization | — | — | — | $17.7M |
| Other OpEx | $158.9M | $127.8M | $33.0M | $5.9M |
| Non-Operating Income | $1.6M | $-12.7M | $-40.7M | $-420.2M |
| Interest Expense | $48.2M | $58.9M | — | — |
| Interest Income | $4.7M | $22.0M | — | $19.0M |
| Pre-Tax Income | $-75.1M | $-81.2M | $88.3M | $-220.8M |
| Income Tax | $11.1M | $-98.9M | $25.1M | $21.6M |
| Continuing Ops | $-86.2M | $17.6M | $63.3M | $-242.4M |
| Discontinued Ops | $0 | $-104.0K | $-18.0K | $-51.0K |
| Net Income | $-86.2M | $17.5M | $63.2M | $-242.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-86.2M | $17.5M | $63.2M | $-242.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $886.1M | $988.2M | $1.13B | $1.10B |
| Cash & Equivalents | $214.2M | $266.5M | $428.9M | $635.6M |
| Accounts Receivable | $183.1M | $215.1M | $193.2M | $216.0M |
| Inventory | $129.4M | $147.9M | $147.6M | $164.7M |
| Prepaid Expenses | $25.0M | $27.2M | $32.4M | $36.8M |
| Other Current Assets | $334.5M | $331.5M | $325.2M | $48.6M |
| Long-Term Assets | $1.41B | $1.44B | $1.38B | $1.50B |
| PP&E (Net) | $147.2M | $154.2M | $170.3M | $242.6M |
| Intangibles | $368.6M | $261.2M | $237.3M | $230.0M |
| Goodwill | $768.8M | $782.9M | $750.0M | $792.8M |
| Operating Leases | $35.8M | $50.8M | $46.8M | $55.5M |
| LT Investments | — | — | — | $20.3M |
| Other LT Assets | $86.3M | $189.3M | $171.1M | $156.4M |
| Total Assets | $2.29B | $2.43B | $2.51B | $2.61B |
| Current Liabilities | $297.4M | $335.0M | $392.1M | $808.1M |
| Accounts Payable | $74.3M | $80.8M | $69.7M | $97.2M |
| Current Debt | $20.9M | $17.5M | $77.3M | $30.9M |
| Current Leases | $9.4M | $8.4M | $9.0M | $8.8M |
| Deferred Revenue | $10.2M | $10.7M | $10.8M | $11.5M |
| Other Current Liab | $107.0M | $110.3M | $106.7M | $565.2M |
| Long-Term Liabilities | $789.8M | $817.0M | $794.0M | $598.0M |
| Long-Term Debt | $518.1M | $568.5M | $549.6M | $345.2M |
| LT Operating Leases | $29.5M | $45.4M | $40.1M | $48.3M |
| Other LT Liab | $228.0M | $187.7M | $189.6M | $186.6M |
| Total Liabilities | $1.09B | $1.15B | $1.19B | $1.41B |
| Shareholders' Equity | $1.21B | $1.28B | $1.32B | $1.20B |
| Retained Earnings | $-984.0M | $-966.5M | $-903.2M | $-1.15B |
| AOCI | $-48.1M | $-27.9M | $-80.2M | $7.3M |
| Treasury Stock | $375.0K | $55.0K | $136.0K | — |
| Total L&E | $2.29B | $2.43B | $2.51B | $2.61B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-86.2M | $17.5M | $63.2M | $-242.5M |
| Non-Cash Adjustments | $135.3M | $-11.2M | $126.1M | $536.4M |
| Working Capital Changes | $20.9M | $68.6M | $-6.3M | $-39.6M |
| Cash from Operations | $69.9M | $74.9M | $183.0M | $254.3M |
| Capital Expenditures | $26.5M | $35.0M | $47.1M | $81.0M |
| Cash from Investing | $-38.4M | $-40.3M | $-48.2M | $-72.9M |
| Debt Issuances | $507.5M | $50.0M | $335.5M | $0 |
| Debt Repayments | $223.5M | $21.6M | $247.5M | $280.9M |
| Cash from Financing | $280.1M | $21.5M | $18.6M | $-285.7M |
| FX Effect | $-4.0M | $6.2M | $-7.7M | $16.2M |
| Net Change in Cash | $307.6M | $62.3M | $145.7M | $-88.0M |
| Beginning Cash | $208.0M | $515.6M | $577.9M | $723.6M |
| Ending Cash | $515.6M | $577.9M | $723.6M | $635.6M |
Frequently Asked Questions
How does LivaNova PLC make money?
The company's revenue is driven primarily by its Cardiovascular Solutions business, which includes durable LVAD products like the HeartMate 3 and HeartMate II pumps as well as disposable drivelines and accessories. A secondary segment involves surgical valves and related consumables sold alongside pump systems. Additionally, the company generates revenue from international sales in Europe and Asia-Pacific regions where it has established significant market presence.
What are the main risks for LIVN?
High regulatory risks from the FDA and EMA regarding product safety approvals and post-market surveillance could delay new product launches or lead to costly recalls. The company faces intense competition from emerging bioprosthetic valve technologies and potential patent expirations that may erode current market share. Dependence on a single major product line exposes LIVN to concentrated revenue risks if the HeartMate 3 faces clinical challenges or supply chain disruptions.
What is LIVN's competitive advantage?
LIVN holds a dominant market position in the durable LVAD space with over 95% global market share for its HeartMate 3 system, creating a high barrier to entry for competitors. The company benefits from strong recurring revenue streams through long-term service contracts and driveline sales associated with implanted devices. Its robust clinical data and continuous innovation pipeline in minimally invasive surgical techniques provide a distinct technological moat.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.